

## **Atara Biotherapeutics Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 06-Jul-2015

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Subsidiary Companies..... 11

Product Portfolio Summary..... 11

Product Portfolio Drugs..... 15

[Return to Table of Contents](#)

# Atara Biotherapeutics Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Atara Biotherapeutics Inc
<b>Parent Company Name</b>	Atara Biotherapeutics Inc
<b>Website</b>	http://www.atarabio.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	6
<b>Number of Inactive Drugs</b>	0
<b>Number of Patents as Owner</b>	10
<b>Number of Patents as Third Party</b>	0
<b>Number of Deals</b>	1
<b>Key Indications</b>	Cancer,Acute lymphoblastic leukemia,Cachexia,End stage renal disease,Protein energy deficiency,Cytomegalovirus infection,Lymphoproliferative disease,Autoimmune disease,Infectious
<b>Key Target-based Actions</b>	GDF-8 antagonist,B-lymphocyte antigen CD19 modulator,CD4 modulator,CD40 ligand modulator,CD47 modulator,Cytotoxic T lymphocyte protein stimulator,Cytotoxic T-lymphocyte protein-4 modulator,Glutamate carboxypeptidase II modulator,HLA class I antigen modulator,HLA class II antigen modulator,Mucin 16 modulator,Prostate stem cell antigen modulator,T-cell surface CD8 beta chain modulator,Wilms tumor protein inhibitor
<b>Key Technologies</b>	Peptide,Intravenous formulation,Antibody fragment,Biological therapeutic,Infusion,T-lymphocyte,Pluripotent stem cell therapy,Antibody,Antigen presentation system,Biochemical synthesis,Cell culture technique,Cell therapy,DNA amplification technology,Embryonic stem cell therapy,Liquid formulation,PCR based technology,RNA amplification

## COMPANY PROFILE

### SUMMARY

Atara Biotherapeutics Inc, which was formed by Amgen and Kleiner Perkins Caufield & Byers, is a drug development company focused on treatments for chronic diseases in areas such as nephrology and oncology.

### FINANCIAL

In February 2015, the company initiated an underwritten public offering of 3 million shares of its common stock and expected to grant the underwriters a 30-day option to purchase up to an additional 0.45 million shares. Later in February 2015, the company priced the public offering of 3,638,333 common stock shares at \$18.00, each. At that time, the underwriters were granted a 30-day option to buy up to an additional 545,749 shares of common stock. The offering was expected to close on February 18, 2015; later that month, the offering was closed. A total of 4,147,358 shares of its common stock were sold including the 509,025 shares, which were pursuant to the partial exercise by the underwriters.

In October 2014, Atara announced the pricing of its initial public offering of 5 million shares of its common stock at a price of \$11 per share. The shares began trading on the NASDAQ global select market under the ticker symbol "ATRA". The company had granted the underwriters a 30-day option to buy up to an additional 750,000 shares of common stock to cover over-allotments, if any. The offering was expected to close on October 21, 2014. Altara began trading on the NASDAQ market on October 16, 2014.

In December 2013, Atara raised \$38.5 million from a series B financing round. In January 2014, a second tranche of the series B financing was closed which bought the total raised in the financing round to \$52 million.

[Return to Table of Contents](#)

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	45.50
Change (USD)	0.17 (0.38%)
Previous Close Price (USD)	45.33
Volume	226,935
52-Week High (USD)	64.35
52-Week Low (USD)	9.66
Date	02-Jul-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	24,364,115
Current Market Capitalization	1,108,567,232
EPS (Date Reported)	-5.61745

STOCK PERFORMANCE




MAJOR SHAREHOLDERS

[Return to Table of Contents](#)

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Haqq (Christopher)	Individual Investor	United States	260,040	1.07	-2,500	-0.01	01-Jul-2015

## FINANCIAL PERFORMANCE



	2012	2013	2014		
<b>Sales (USD M)</b>	0	0	0		
<b>Operating Income (USD M)</b>	-4.093	-8.615	-28.156		
<b>Net Income (USD M)</b>	-4.11	-8.773	-28.006		

[Return to Table of Contents](#)



## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2015 Q1	0	-9.311	-9.16
2014 Q4	0	-10.596	-10.527
2014 Q3	0	-5.949	-5.919
2014 Q2	0	-4.534	-4.511
2014 Q1	0	-7.077	-7.049
2013 Q2	0	-1.361	-1.383
2013 Q1	0	-1.286	-1.298

## BALANCE SHEET

### Assets (USD M)

	2012	2013	2014		
Cash & Short Term Investments	4.207	51.615	104.116		
Inventories - Total	0	0	0		
Current Assets - Total	4.242	51.808	106.026		
Property, Plant And Equipment - Net	0.009	0.008	0.048		
Other Assets - Total	0.039	0.012	0.048		
Total Assets	4.29	52.163	106.122		

### Liabilities (USD M)

	2012	2013	2014		
Accounts Payable	0.121	0.606	0.44		
Short Term Debt & Current Portion Of Long Term Debt	0	0	0		
Current Liabilities - Total	1.302	1.524	2.724		
Long Term Debt	0	0	0		
Other Liabilities	0.004	0.23	0.216		
Total Liabilities	1.306	1.754	2.94		

[Return to Table of Contents](#)



## Stockholders Equity (USD M)

	2012	2013	2014		
Minority Interest	0	0	0		
Preferred Stock	6.711	61.091	0		
Common Stock	0.001	0.001	0.002		
Treasury Stock	0				
Total Liabilities & Shareholders' Equity	4.29	52.163	106.122		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.94	-1.76	-1.91
31-Dec-2016	-2.94	-2.81	-2.65
31-Dec-2017	-3.19	-3.06	-2.91

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0		-44.97	0
31-Dec-2016	0		-74.05	0
31-Dec-2017	0		-87.92	0

## SUBSIDIARY COMPANIES

Names
Pinta Biotherapeutics


[Return to Table of Contents](#)

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	0	3
Nutritional disorder	2	0	2
Immune disorder	1	0	1
Hematological disease	1	0	1
Infectious disease	1	0	1
Genitourinary disease	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	3
Phase 1 Clinical	2
Discovery	1

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	0	0	1	0	1

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Genitourinary disease	1	1

Trials by Phase

Phase	Ongoing	All
-------	---------	-----

[Return to Table of Contents](#)

## Trials by Phase

Phase	Ongoing	All
Phase 1	1	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Endocrine disease	6	0	6
Gastrointestinal disease	4	0	4
Genitourinary disease	6	0	6
Growth disorder	3	0	3
Hematological disease	7	0	7
Andrology	3	0	3
Immune disorder	6	0	6
Musculoskeletal disease	3	0	3
Neoplasm	11	0	11
Metabolic disorder	3	0	3
Neurological disease	2	0	2
Nutritional disorder	3	0	3
Respiratory disease	3	0	3
Infectious disease	4	0	4
Injury	2	0	2
Inflammatory disease	2	0	2
Gynecology and obstetrics	5	0	5

[Return to Table of Contents](#)



Dermatological disease	2	0	2
Surgical procedure	3	0	3

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### EBV-CTL

<b>Drug Name</b>	EBV-CTL
<b>Key Synonyms</b>	
<b>Originator Company</b>	Memorial Sloan-Kettering Cancer Center
<b>Active Companies</b>	Atara Biotherapeutics Inc
<b>Inactive Companies</b>	Memorial Sloan-Kettering Cancer Center
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Acute lymphoblastic leukemia, Lymphoproliferative disease
<b>Target-based Actions</b>	B-lymphocyte antigen CD19 inhibitor
<b>Other Actions</b>	T-lymphocyte modulator, Anticancer
<b>Technologies</b>	T-lymphocyte, Cell therapy, Systemic formulation unspecified, Infusion, Small molecule therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	29-Jun-2015

### CMV-CTL

<b>Drug Name</b>	CMV-CTL
<b>Key Synonyms</b>	
<b>Originator Company</b>	Memorial Sloan-Kettering Cancer Center
<b>Active Companies</b>	Atara Biotherapeutics Inc
<b>Inactive Companies</b>	Memorial Sloan-Kettering Cancer Center
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Cytomegalovirus infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	T-lymphocyte modulator, Antiviral, CMV replication inhibitor
<b>Technologies</b>	T-lymphocyte, Cell therapy, Intravenous formulation, Infusion, Biological therapeutic
<b>Last Change Date</b>	16-Jun-2015

[Return to Table of Contents](#)



## PINTA-745

<b>Drug Name</b>	PINTA-745
<b>Key Synonyms</b>	
<b>Originator Company</b>	Atara Biotherapeutics Inc
<b>Active Companies</b>	Atara Biotherapeutics Inc, Pinta Biotherapeutics
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Protein energy deficiency, End stage renal disease
<b>Target-based Actions</b>	GDF-8 antagonist
<b>Other Actions</b>	
<b>Technologies</b>	Antibody fragment, Intravenous formulation, Infusion, Biological therapeutic, Peptide
<b>Last Change Date</b>	03-Apr-2015

## WT1-CTL

<b>Drug Name</b>	WT1-CTL
<b>Key Synonyms</b>	
<b>Originator Company</b>	Memorial Sloan-Kettering Cancer Center
<b>Active Companies</b>	Atara Biotherapeutics Inc
<b>Inactive Companies</b>	Formula Pharmaceuticals Inc, Memorial Sloan-Kettering Cancer Center
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Wilms tumor protein inhibitor
<b>Other Actions</b>	Anticancer, T-lymphocyte modulator
<b>Technologies</b>	T-lymphocyte, Tumor antigen therapeutic, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	16-Jun-2015

[Return to Table of Contents](#)





**STM-434**

<b>Drug Name</b>	STM-434
<b>Key Synonyms</b>	
<b>Originator Company</b>	Amgen Inc
<b>Active Companies</b>	Amgen Inc, Atara Biotherapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Activin type-IIb receptor antagonist
<b>Other Actions</b>	Synergist, Anticancer protein kinase inhibitor
<b>Technologies</b>	Antibody fragment, Biological therapeutic, Parenteral formulation unspecified, Protein fusion
<b>Last Change Date</b>	23-Oct-2014

**ATA-842**

<b>Drug Name</b>	ATA-842
<b>Key Synonyms</b>	
<b>Originator Company</b>	Amgen Inc
<b>Active Companies</b>	Atara Biotherapeutics Inc
<b>Inactive Companies</b>	Amgen Inc
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cachexia
<b>Target-based Actions</b>	GDF-8 antagonist
<b>Other Actions</b>	
<b>Technologies</b>	Humanized antibody, Systemic formulation unspecified, Biological therapeutic
<b>Last Change Date</b>	12-Feb-2015

[Return to Table of Contents](#)


This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

